R. Michael Carruthers

Michael Carruthers currently serves as the Chief Financial Officer of Edgewise Therapeutics (NASDAQ: EWTX). Mr. Carruthers has over 20 years of experience serving as Chief Financial Officer for publicly-traded biopharmaceutical companies, with extensive experience across corporate finance and strategic planning including IPOs, secondary offerings, and M&A transactions. Most recently, Mr. Carruthers consulted as Chief Financial Officer for several private and public companies. Previously, Mr. Carruthers served as Interim President of Nivalis Therapeutics, a publicly-traded company acquired by Alpine Immune Sciences, in 2017, and Chief Financial Officer and Secretary from 2015 to 2017. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma Inc., a publicly-traded company acquired by Pfizer Inc. Prior to this, he served as Chief Financial Officer of Sievers Instruments, Treasurer and Controller for the Waukesha division of Dover Corporation, and Accountant with Coopers & Lybrand. Mr. Carruthers received a B.S. in Accounting from the University of Colorado and an M.B.A. from the University of Chicago.